Henk Mallo

2.1k total citations
24 papers, 447 citations indexed

About

Henk Mallo is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Henk Mallo has authored 24 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Henk Mallo's work include Cancer Immunotherapy and Biomarkers (8 papers), Renal cell carcinoma treatment (6 papers) and CAR-T cell therapy research (6 papers). Henk Mallo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Renal cell carcinoma treatment (6 papers) and CAR-T cell therapy research (6 papers). Henk Mallo collaborates with scholars based in Netherlands, Australia and Sweden. Henk Mallo's co-authors include John B.A.G. Haanen, Astrid A.M. van der Veldt, Epie Boven, Helgi H. Helgason, Axel Bex, Simon Horenblas, Johannes Berkhof, Alfons J.M. van den Eertwegh, Christian U. Blank and Johan Sein and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Henk Mallo

22 papers receiving 443 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Henk Mallo Netherlands	12	236	183	167	141	65	24	447
Maria Marples United Kingdom	10	512 2.2×	357 2.0×	176 1.1×	69 0.5×	41 0.6×	31	722
K. Nathan Sankar United States	14	269 1.1×	170 0.9×	124 0.7×	80 0.6×	80 1.2×	41	526
Nada Babović Serbia	14	258 1.1×	114 0.6×	98 0.6×	319 2.3×	59 0.9×	34	611
Jason B. Litten United States	9	132 0.6×	87 0.5×	202 1.2×	130 0.9×	87 1.3×	21	537
Davide Bosso Italy	12	132 0.6×	167 0.9×	133 0.8×	41 0.3×	70 1.1×	18	366
Annelieke E.C.A.B. Willemsen Netherlands	10	145 0.6×	102 0.6×	89 0.5×	40 0.3×	23 0.4×	25	298
Renata Lottici Italy	7	296 1.3×	118 0.6×	123 0.7×	51 0.4×	45 0.7×	9	386
Victoria Atkinson Australia	13	480 2.0×	109 0.6×	270 1.6×	181 1.3×	26 0.4×	41	591
Meagan S. Barbee United States	6	232 1.0×	91 0.5×	71 0.4×	82 0.6×	21 0.3×	8	331
Smitha Menon United States	11	300 1.3×	128 0.7×	134 0.8×	75 0.5×	73 1.1×	18	474

Countries citing papers authored by Henk Mallo

Since Specialization

Citations

This map shows the geographic impact of Henk Mallo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henk Mallo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henk Mallo more than expected).

Fields of papers citing papers by Henk Mallo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henk Mallo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henk Mallo. The network helps show where Henk Mallo may publish in the future.

Co-authorship network of co-authors of Henk Mallo

This figure shows the co-authorship network connecting the top 25 collaborators of Henk Mallo. A scholar is included among the top collaborators of Henk Mallo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henk Mallo. Henk Mallo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tibollo, Valentina, Henk Mallo, Sofie Wilgenhof, et al.. (2024). Usability and Usefulness of a Symptom Management Coaching System for Patients With Cancer Treated With Immune Checkpoint Inhibitors: Comparative Mixed Methods Study. JMIR Formative Research. 9. e57659–e57659.

Rozeman, Elisa A., Judith M. Versluis, Alexander M. Menzies, et al.. (2023). 1096P Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma. Annals of Oncology. 34. S660–S661. 1 indexed citations

Versluis, Judith M., Sofie Wilgenhof, A. Meerveld-Eggink, et al.. (2022). 854P Clinical features of acquired resistance (AR) in stage IV melanoma patients (pts) treated with immune checkpoint inhibition (ICI). Annals of Oncology. 33. S940–S940. 1 indexed citations

Wilgenhof, Sofie, Stephanie Medlock, Henk Mallo, et al.. (2022). Exploring supportive care and information needs through a proposed eHealth application among melanoma patients undergoing systemic therapy: a qualitative study. Supportive Care in Cancer. 30(9). 7249–7260. 12 indexed citations

Rozeman, Elisa A., Warner Prevoo, Mark A. Meier, et al.. (2020). Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM). Melanoma Research. 30(3). 252–260. 38 indexed citations

Blank, Christian U., Judith M. Versluis, Karolina Sikorska, et al.. (2019). 3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial). Annals of Oncology. 30. v535–v535. 12 indexed citations

Sikorska, Karolina, Lindsay G. Grijpink-Ongering, Bart A. van de Wiel, et al.. (2018). Phase II study comparing pembrolizumab (PEM) with intermittent/short‐term dual MAPK pathway inhibition plus PEM in patients harboring the BRAFV600 mutation (IMPemBra). Annals of Oncology. 29. viii736–viii736. 7 indexed citations

Lankheet, Nienke A. G., Alwin D. R. Huitema, Henk Mallo, et al.. (2013). The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand–foot syndrome. European Journal of Clinical Pharmacology. 69(12). 2065–2072. 6 indexed citations

Tjin, Esther P.M., Debby Konijnenberg, Henk Mallo, et al.. (2011). T-Cell Immune Function in Tumor, Skin, and Peripheral Blood of Advanced Stage Melanoma Patients: Implications for Immunotherapy. Clinical Cancer Research. 17(17). 5736–5747. 32 indexed citations

10.

Lankheet, Nienke A. G., Christian U. Blank, Henk Mallo, et al.. (2011). Determination of Sunitinib and Its Active Metabolite N-Desethylsunitinib in Sweat of a Patient. Journal of Analytical Toxicology. 35(8). 558–565. 30 indexed citations

11.

Lankheet, Nienke A. G., Henk Mallo, J.B.A.G. Haanen, et al.. (2010). Quantification of sunitinib in sweat secretion.. Journal of Clinical Oncology. 28(15_suppl). e15094–e15094. 1 indexed citations

12.

Veldt, Astrid A.M. van der, Epie Boven, Helgi H. Helgason, et al.. (2008). Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. British Journal of Cancer. 99(2). 259–265. 103 indexed citations

13.

Bins, Adriaan D., Henk Mallo, Johan Sein, et al.. (2007). Phase I Clinical Study With Multiple Peptide Vaccines in Combination With Tetanus Toxoid and GM-CSF in Advanced-stage HLA-A*0201-positive Melanoma Patients. Journal of Immunotherapy. 30(2). 234–239. 19 indexed citations

14.

Helgason, Helgi H., et al.. (2007). Brain Metastases in Patients With Renal Cell Cancer Receiving New Targeted Treatment. Journal of Clinical Oncology. 26(1). 152–154. 38 indexed citations

15.

Bex, Axel, et al.. (2005). Interferon alpha 2b as Medical Selection for Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma: A Consecutive Study. European Urology. 49(1). 76–81. 27 indexed citations

16.

Kerst, J. Martijn, Axel Bex, Henk Mallo, et al.. (2005). Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. Cancer Immunology Immunotherapy. 54(9). 926–931. 11 indexed citations

17.

Bex, Axel, et al.. (2005). Extended Continuous Oral Temozolomide in Patients with Progressive Metastatic Renal Cell Carcinoma Not Responding to Interferon Alpha 2b. Journal of Chemotherapy. 17(6). 674–678. 2 indexed citations

18.

Bex, Axel, Henk Mallo, Martijn Kerst, et al.. (2004). A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. Cancer Immunology Immunotherapy. 54(7). 713–719. 20 indexed citations

19.

Bins, Adriaan D., Sjoerd G. Elias, Johan Sein, et al.. (2004). On the Role of Melanoma-Specific CD8+ T-Cell Immunity in Disease Progression of Advanced-Stage Melanoma Patients. Clinical Cancer Research. 10(14). 4754–4760. 41 indexed citations

20.

Jansen, Slinger, Gerard Groenewegen, Henk Mallo, et al.. (2003). Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma. British Journal of Cancer. 88(9). 1346–1351. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact